Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors

Sabat, Mark; Wang, Haixia; Scorah, Nick; Lawson, J. David; Atienza, Joy; Kamran, Ruhi; Hixon, Mark S.; Dougan, Douglas R.

doi:10.1016/j.bmcl.2017.03.026

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors

Journal Article · Mon May 01 00:00:00 UTC 2017 · Bioorganic and Medicinal Chemistry Letters

DOI:https://doi.org/10.1016/j.bmcl.2017.03.026· OSTI ID:1413802

Sabat, Mark; Wang, Haixia; Scorah, Nick; Lawson, J. David; Atienza, Joy; Kamran, Ruhi; Hixon, Mark S.; Dougan, Douglas R.

Not Available

View Accepted Manuscript (Publisher)

Sponsoring Organization:: USDOE Office of Science (SC), Basic Energy Sciences (BES)

Grant/Contract Number:: AC02-05CH11231

OSTI ID:: 1413802

Journal Information:: Bioorganic and Medicinal Chemistry Letters, Journal Name: Bioorganic and Medicinal Chemistry Letters Journal Issue: 9 Vol. 27; ISSN 0960-894X

Publisher:: ElsevierCopyright Statement

Country of Publication:: United Kingdom

Language:: English

References (24)

XtalView/Xfit—A Versatile Program for Manipulating Atomic Coordinates and Electron Density McRee, Duncan E. Journal of Structural Biology, Vol. 125, Issue 2-3 https://doi.org/10.1006/jsbi.1999.4094	journal	April 1999
EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling Park, Sang-A; Kim, Min-Jin; Park, So-Yeon Cellular and Molecular Life Sciences, Vol. 72, Issue 10 https://doi.org/10.1007/s00018-014-1798-6	journal	December 2014
[20] Processing of X-ray diffraction data collected in oscillation mode Otwinowski, Zbyszek; Minor, Wladek Macromolecular Crystallography Part A, 307-326 https://doi.org/10.1016/S0076-6879(97)76066-X	book	January 1997
Ligand efficiency: a useful metric for lead selection Hopkins, Andrew L.; Groom, Colin R.; Alex, Alexander Drug Discovery Today, Vol. 9, Issue 10 https://doi.org/10.1016/S1359-6446(04)03069-7	journal	May 2004
Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI) Singh, Juswinder; Chuaqui, Claudio E.; Boriack-Sjodin, P. Ann Bioorganic & Medicinal Chemistry Letters, Vol. 13, Issue 24 https://doi.org/10.1016/j.bmcl.2003.09.028	journal	December 2003
Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors Gellibert, F.; Fouchet, M. -H.; Nguyen, V. -L. Bioorganic & Medicinal Chemistry Letters, Vol. 19, Issue 8 https://doi.org/10.1016/j.bmcl.2009.02.087	journal	April 2009
Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring Boys, Mark L.; Bian, Feng; Kramer, James B. Bioorganic & Medicinal Chemistry Letters, Vol. 22, Issue 10 https://doi.org/10.1016/j.bmcl.2012.04.013	journal	May 2012
Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors Wang, Haixia; Lawson, J. David; Scorah, Nick Bioorganic & Medicinal Chemistry Letters, Vol. 26, Issue 17 https://doi.org/10.1016/j.bmcl.2016.07.030	journal	September 2016
Discovery of N -((4-([1,2,4]Triazolo[1,5- a ]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1 H -imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent Jin, Cheng Hua; Krishnaiah, Maddeboina; Sreenu, Domalapally Journal of Medicinal Chemistry, Vol. 57, Issue 10 https://doi.org/10.1021/jm500115w	journal	May 2014
Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent Li, Hong-yu; McMillen, William T.; Heap, Charles R. Journal of Medicinal Chemistry, Vol. 51, Issue 7 https://doi.org/10.1021/jm701199p	journal	April 2008
The influence of drug-like concepts on decision-making in medicinal chemistry Leeson, Paul D.; Springthorpe, Brian Nature Reviews Drug Discovery, Vol. 6, Issue 11 https://doi.org/10.1038/nrd2445	journal	November 2007
An Activin Receptor-Like Kinase 5 Inhibitor Reduces Collagen Deposition in a Rat Dermal Incision Wound Healing Model Bian, Feng; Render, James; Ren, Xiao-Dan Plastic and Reconstructive Surgery, Vol. 128, Issue 5 https://doi.org/10.1097/PRS.0b013e31822b65c7	journal	January 2011
Phaser crystallographic software McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D. Journal of Applied Crystallography, Vol. 40, Issue 4 https://doi.org/10.1107/S0021889807021206	journal	July 2007
MOLREP an Automated Program for Molecular Replacement Vagin, A.; Teplyakov, A. Journal of Applied Crystallography, Vol. 30, Issue 6, p. 1022-1025 https://doi.org/10.1107/S0021889897006766	journal	December 1997
Refinement of Macromolecular Structures by the Maximum-Likelihood Method Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Acta Crystallographica Section D Biological Crystallography, Vol. 53, Issue 3 https://doi.org/10.1107/S0907444996012255	journal	May 1997
SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7 Inman, Gareth J.; Nicolás, Francisco J.; Callahan, James F. Molecular Pharmacology, Vol. 62, Issue 1 https://doi.org/10.1124/mol.62.1.65	journal	July 2002
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors Anderton, Mark J.; Mellor, Howard R.; Bell, Alex Toxicologic Pathology, Vol. 39, Issue 6 https://doi.org/10.1177/0192623311416259	journal	August 2011
Definition of the hydrogen bond (IUPAC Recommendations 2011) Arunan, Elangannan; Desiraju, Gautam R.; Klein, Roger A. Pure and Applied Chemistry, Vol. 83, Issue 8 https://doi.org/10.1351/PAC-REC-10-01-02	journal	July 2011
Activin receptor antagonists for cancer-related anemia and bone disease Fields, Scott Z.; Parshad, Shiroo; Anne, Madhurima Expert Opinion on Investigational Drugs, Vol. 22, Issue 1 https://doi.org/10.1517/13543784.2013.738666	journal	November 2012
TGF-beta Signaling in Cancer Treatment Fabregat, Isabel; Fernando, Joan; Mainez, Jessica Current Pharmaceutical Design, Vol. 20, Issue 17 https://doi.org/10.2174/13816128113199990591	journal	May 2014
TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology E. Ling, Leona; Lee, Wen-Cherng Current Pharmaceutical Biotechnology, Vol. 12, Issue 12 https://doi.org/10.2174/138920111798808257	journal	December 2011
Predicting Clearance in Humans from In Vitro Data Scott Obach, R. Current Topics in Medicinal Chemistry, Vol. 11, Issue 4 https://doi.org/10.2174/156802611794480873	journal	February 2011
Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis Koh, Rhun Yian; Lim, Chooi Ling; Uhal, Bruce David Molecular Medicine Reports, Vol. 11, Issue 5 https://doi.org/10.3892/mmr.2015.3193	journal	January 2015
Complexities of TGF-β Targeted Cancer Therapy Connolly, Erin C.; Freimuth, Julia; Akhurst, Rosemary J. International Journal of Biological Sciences, Vol. 8, Issue 7 https://doi.org/10.7150/ijbs.4564	journal	January 2012

Similar Records

Synthesis, structure, and properties of pyrazolo(4,3-b)quinuclidine derivatives

Journal Article · Sat Mar 01 04:00:00 UTC 1986 · Chem. Heterocycl. Compd. (Engl. Transl.); (United States) · OSTI ID:6033887

Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors

Journal Article · Fri Oct 01 04:00:00 UTC 2010 · Bioorg. Med. Chem. Lett. · OSTI ID:1007159

Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase

Journal Article · Wed Sep 25 04:00:00 UTC 2019 · ACS Medicinal Chemistry Letters · OSTI ID:1577173

Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors

Citation Formats

References (24)

Similar Records

Related Subjects